PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 20.95

Change

-0.24 (-1.13)%

Market Cap

N/A

Volume

0.50M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.93 (+1.25%)

USD 10.78B
DOCS Doximity Inc

+1.07 (+2.53%)

USD 7.80B
WEAV Weave Communications Inc

+0.02 (+0.14%)

USD 1.02B
MPLN MultiPlan Corporation

+0.59 (+7.17%)

USD 0.14B
AMWL American Well Corp

+0.07 (+0.79%)

USD 0.14B
OWLT Owlet Inc

-0.06 (-1.16%)

USD 0.08B
TDOC Teladoc Inc

+0.07 (+0.74%)

N/A
FOXO FOXO Technologies Inc.

-0.41 (-52.89%)

N/A
EVH Evolent Health Inc

-0.20 (-0.81%)

N/A
VEEV Veeva Systems Inc Class A

+6.94 (+3.21%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.50% 30% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.50% 30% F 25% F
Trailing 12 Months  
Capital Gain 43.69% 40% F 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.69% 40% F 81% B-
Trailing 5 Years  
Capital Gain -29.46% 50% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.46% 50% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 13.32% 80% B- 74% C
Dividend Return 13.32% 80% B- 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.18% 60% D- 13% F
Risk Adjusted Return 19.53% 80% B- 37% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector